Original Article

You have full text access to this OnlineOpen article

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

  1. Robert Perrillo M.D.1,*,
  2. Eugene Schiff2,
  3. Eric Yoshida3,
  4. Ann Statler2,
  5. Kenneth Hirsch4,
  6. Teresa Wright4,
  7. Klaus Gutfreund5,
  8. Patrick Lamy6,
  9. Alison Murray6

Article first published online: 30 DEC 2003

DOI: 10.1053/jhep.2000.8626

Issue

Hepatology

Hepatology

Volume 32, Issue 1, pages 129–134, July 2000

Additional Information

How to Cite

Perrillo, R., Schiff, E., Yoshida, E., Statler, A., Hirsch, K., Wright, T., Gutfreund, K., Lamy, P. and Murray, A. (2000), Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology, 32: 129–134. doi: 10.1053/jhep.2000.8626

Author Information

  1. 1

    Ochsner Clinic, New Orleans, LA; Vancouver, BC, Canada

  2. 2

    University of Miami, Miami, FL; Vancouver, BC, Canada

  3. 3

    Department of Medicine, University of British Columbia, Vancouver, BC, Canada

  4. 4

    University of California, San Francisco, CA

  5. 5

    University of Alberta, Alberta, Canada

  6. 6

    Gilead Sciences Inc., Foster City, CA

*1514 Jefferson Highway, New Orleans, LA 70121. fax: 504-842-7466.

Publication History

  1. Issue published online: 30 DEC 2003
  2. Article first published online: 30 DEC 2003
  3. Manuscript Accepted: 20 APR 2000
  4. Manuscript Received: 17 FEB 2000

Funded by

  • A.M.'s current address is Roche Molecular Systems, Pleasanton, CA

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (91K)

REFERENCES

  • 1
    Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61–68.MEDLINE
  • 2
    Schiff E, Karayalcin S, Grimm I, Perrillo R, Dienstag J, Husa P, Schalm S, et al. A placebo controlled study of lamivudine and interferon alpha 2b in patients with chronic hepatitis B who previously failed interferon therapy [Abstract]. Hepatology 1998; 28(Suppl):388A.
  • 3
    Heathcote J, Schalm SW, Ciancara J, Farrell G, Sherman M, Willems B, Dhillon A, et al. Lamivudine and intron A combination treatment in patients with chronic hepatitis B infection [Abstract]. J Hepatol 1998; 28:43.
  • 4
    Perrillo RP, Rakela J, Dienstag J, Levy G, Martin P, Wright T, Caldwell S, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29:1581–1586.MEDLINE
    Direct Link:
  • 5
    Allen M, Deslauriers M, Andrews C, Tipples G, Walters KA, Tyrrell D, Brown N, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27:1670–1677.MEDLINE
    Direct Link:
  • 6
    Atkins M, Hunt CM, Gray F, Sanathanan L, Woessner M, Lai CL, Dusheiko G, et al. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients [Abstract]. Hepatology 1998; 28(Suppl):319A.
  • 7
    Liaw YF, Lai CL, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, et al. Two year lamivudine therapy in chronic hepatitis B infection: results of a placebo-controlled multicentre study in Asia [Abstract]. Gastroenterology 1998; 114(Suppl):1289.
  • 8
    Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Wu PC, et al. Three year lamivudine therapy in chronic HBV [Abstract]. J Hepatol 1999; 30:59.
  • 9
    Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LC, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:20–22.MEDLINE
  • 10
    Yoshida EM, Ma MM, Davis JE, Fischer KP, Kneteman NM, Erb SR, Tyrrell DL, et al. Post liver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: long term follow up. Can J Gastroenterol 1998; 12:125–129.MEDLINE
  • 11
    Shields PL, Ling R, Harrison T, Boxall E, Elias E, Mutimer DJ. Management and outcome of lamivudine (LAM) resistant hepatitis B virus (HBV) infection after liver transplantation [Abstract ]. Hepatology 1997; 26(Suppl):260A.
  • 12
    Wolters LMM, Honkoop P, de Man RA, Niesters HGM, Schalm SW. Famciclovir treatment in lamivudine resistant chronic hepatitis B [Abstract]. J Hepatol 1998; 28:113.
  • 13
    Xiong K, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28:1669–1673.MEDLINE
    Direct Link:
  • 14
    Xiong X, Yang H, Westland CE, Toole JJ, Gibbs CS. Human hepatitis B virus DNA polymerases which contain mutations arising during famciclovir treatment remain sensitive to adefovir [Abstract]. Hepatology 1998; 28(Suppl):491A.
  • 15
    Gilson RJC, Chopra KB, Newell AM, Murray-Lyon IM, Nelson MR, Rice SJ, Tedder RS, et al. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepatitis 1999; 6:387–395.
    Direct Link:
  • 16
    Heathcote E, Jeffers L, Wright T, Sherman M, Perrillo R, Sacks S, Carithers R, et al. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies [Abstract]. Hepatology 1998; 28(Suppl):317A.
  • 17
    Gutfreund KS, Fischer KP, Bain VG, Ma M, Williams M, Yoshida E, Villeneuve JP, et al. Genotypic succession of mutations of the HBV polymerase associated with lamivudine resistance in chronic hepatitis B and liver transplantation [Abstract]. Hepatology 1998; 28(Suppl):487A.
  • 18
    Aye TY, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26:1148–1153.MEDLINE
  • 19
    Tillmann HL, Trautwein C, Bock T, Boker K HW, Jackel E, Gowienka M, Oldhafer K, et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 1999; 30:244–256.MEDLINE
    Direct Link:
  • 20
    Ono-Nita SK, Kato N, Shiratori Y, Lan KH, Yoshida H, Kato J, Carrilho FJ, et al. Susceptibility of lamivudine resistant hepatitis B virus to other antivirals: adefovir and lobucavir [Abstract]. Hepatology 1998; 28(Suppl):165A.
  • 21
    Tur Kaspa R, Burk RD, Shaul Y, Shafritz D. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A 1986; 83:1627–1633.MEDLINE
  • 22
    Cote PJ, Korba BE, Steinberg H, Ramirez-Mejia C, Baldwin B, Hornbuckle WE, Tennant BC, et al. Cyclosporin A modulates the course of woodchuck hepatitis virus infection and induces chronicity. J Immunol 1991; 146:3138–3144.MEDLINE
  • 23
    Gallant J, Naeger L, Beal J, Myers R, Peterson D, Bruce J, Peschell K, et al. Adefovir Dipivoxil (ADV) 60 mg and 120 mg in combination regimens for PI-naïve patients [Abstract]. 7th Conference on Retroviruses and Opportunistic Infections 2000;528.
  • 24
    Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, Hardy D, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy. A randomized, controlled trial. JAMA 1999; 282:2305–2312.MEDLINE
Get PDF (91K)